<DOC>
	<DOCNO>NCT01631526</DOCNO>
	<brief_summary>Hypovitaminosis D highly prevalent people lung cancer , may adverse clinical consequence . The long variable pharmacokinetic half-life vitamin D make prompt vitamin D replacement problematic . This open , one-armed therapeutic intervention use load dose vitamin D predict increase plasma 25-hydroxyvitamin D concentration every patient well normal range ( &gt; 100 nmol/L ) within 2 3 week monitor 2 3 week load maintenance dose . Preliminary data also obtain identify potentially clinical important outcome benefit future investigation . The outcome 1. plasma 25OHD concentration 2 . Vitamin D bind protein plasma concentration 3 . Mood symptom</brief_summary>
	<brief_title>Vitamin D Loading Dose Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Any patient advance lung cancer whether receive specific anticancer therapy 2 . Mentally competent ( need fluent French English capable neutral translator available ) 3 . Self report reduce food intake and/or involuntary weight loss extent time enrollment : documented 1 . Current diagnosis primary hyperparathyroidism 2 . Nephrocalcinosis 3 . Current suspect active tuberculosis , histoplasmosis , sarcoidosis , granulomatous disease 4 . Current use vitamin D supplement provide &gt; 1000 IU/day 5 . Current prescribed calcitriol dose 6 . History extensive sunlight exposure ( &gt; 30 min summer sunlight exposure per day 5 day per week ) previous 3 month 7 . Expected die within next 2 month 8 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>vitamin D</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>